Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24354973 | 1.00 | ATM (0.44) | ATMPLA2G1BATG4BACEGAA | |
| SCHEMBL29108935 | 1.00 | ATM (0.44) | ATMPLA2G1BATG4BACEGAA | |
| SCHEMBL4072231 | 1.00 | ATM (0.44) | ATMPLA2G1BATG4BACEGAA | |
| SCHEMBL10330907 | 1.00 | ATM (0.44) | ATMPLA2G1BATG4BACEGAA | |
| SCHEMBL13164365 | 1.00 | ATM (0.44) | ATMPLA2G1BATG4BACEGAA | |
| SCHEMBL8989612 | 0.82 | ATM (0.59) | ATMACEGAATDP1ALDH1A1 | |
| SCHEMBL16174139 | 0.82 | ATM (0.35) | ATMGAA | |
| SCHEMBL1303907 | 0.82 | ATM (0.59) | ATMACEGAATDP1ALDH1A1 | |
| SCHEMBL589712 | 0.82 | ATM (0.59) | ATMACEGAATDP1ALDH1A1 | |
| SCHEMBL7882438 | 0.82 | ATM (0.59) | ATMACEGAATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024035622-A1 | INHIBITORS OF cGAS ACTIVITY AS THERAPEUTIC AGENTS | BELLBROOK LABS, LLC (US) | 2024-02-15 | — | — | WO | disclosed |
| CN-116802184-A | Pyrazolothiazole carboxamides and their use as PDGFR inhibitors | 埃科特莱茵药品有限公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ABAC Therapeutics, S.L. (ES) | 2021-02-16 | — | — | US | disclosed |
| EP-3490984-B1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | Abac Therapeutics Sl (ES) | 2020-09-09 | — | — | EP | disclosed |
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC Therapeutics, S.L. (ES) | 2019-06-13 | — | — | US | disclosed |
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ABAC Therapeutics, S.L. (ES) | 2019-06-13 | — | — | US | disclosed |
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-18 | — | — | US | disclosed |
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | MEDIVIR AB | 2010-02-18 | — | — | US | disclosed |
| US-20100022578-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-28 | — | — | US | disclosed |
| US-20090324511-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-11-12 | — | — | US | disclosed |
| US-20090247512-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090176307-A1 | Compounds, Compositions and Methods | CYTOKINETICS, INC. | 2009-07-09 | — | — | US | disclosed |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-04-23 | — | — | US | disclosed |
| US-20090062311-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | ATM 4045/4885PLA2G1B 3917/4885ATG4B 2932/4885 |
| US-20100041728-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | COPB1, HAVCR2, NOD1 | ATM 4346/4885PLA2G1B 4035/4885ATG4B 984/4885 |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | ATM 4045/4885PLA2G1B 3917/4885ATG4B 2932/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | ATM 3758/4885PLA2G1B 3364/4885ATG4B 2681/4885 |
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CBR1, HCCS, CYP2B6 | ATM 4429/4885PLA2G1B 4436/4885ATG4B 3157/4885 |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, EIF2AK2 | ATM 3595/4885PLA2G1B 4511/4885ATG4B 2772/4885 |
| US-20190177272-A1 | 2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS | ATAD2, ATAD2B, ATAD5 | ATM 2583/4885PLA2G1B 3360/4885ATG4B 1109/4885 |
| US-20100022578-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, HCCS, IFNAR1 | ATM 4417/4885PLA2G1B 4161/4885ATG4B 3334/4885 |
| US-20090324511-A1 | Compounds, Compositions and Methods | TNNI3, TNNC1, TNNT2 | ATM 3258/4885PLA2G1B 2882/4885ATG4B 3985/4885 |
| US-20170137412-A1 | SUBSTITUTED PYRROLIDINES AS FACTOR XIA INHIBITORS FOR THE TREATMENT THROMBOEMBOLIC DISEASES | F11, F9, F10 | ATM 4463/4885PLA2G1B 2155/4885ATG4B 4067/4885 |
| US-20090105302-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HCCS, CBR1, CYP2B6 | ATM 4503/4885PLA2G1B 3784/4885ATG4B 3988/4885 |
| US-20090062311-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | HCCS, NR5A1, NR0B1 | ATM 4845/4885PLA2G1B 3494/4885ATG4B 3269/4885 |
| US-10919851-B2 | 2-pyrrolidine phenylhydrazides antibacterial agents | ATAD2, ATAD2B, ATAD5 | ATM 2583/4885PLA2G1B 3360/4885ATG4B 1109/4885 |
| US-20090247512-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP2B6, HCCS | ATM 3919/4885PLA2G1B 3681/4885ATG4B 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.